UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Phosphorothioate modified oligonucleotide–protein interactions

Nucleic acids research, 2020-06, Vol.48 (10), p.5235-5253

2020

Volltextzugriff (PDF)

Cellular uptake and trafficking of antisense oligonucleotides

Nature biotechnology, 2017-03, Vol.35 (3), p.230-237

2017

Volltextzugriff (PDF)

Development of a Quantitative BRET Affinity Assay for Nucleic Acid-Protein Interactions

PloS one, 2016-08, Vol.11 (8), p.e0161930-e0161930

2016

Volltextzugriff (PDF)

Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials

The Lancet (British edition), 2016-11, Vol.388 (10057), p.2239-2253

2016

Volltextzugriff (PDF)

Single-Stranded RNAs Use RNAi to Potently and Allele-Selectively Inhibit Mutant Huntingtin Expression

Cell, 2012-08, Vol.150 (5), p.895-908

2012

Volltextzugriff (PDF)

Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index

Nature biotechnology, 2019-06, Vol.37 (6), p.640-650

2019

Volltextzugriff (PDF)

Clinical and Preclinical Pharmacokinetics and Pharmacodynamics of Mipomersen (Kynamro®): A Second-Generation Antisense Oligonucleotide Inhibitor of Apolipoprotein B

Clinical pharmacokinetics, 2015-02, Vol.54 (2), p.133-146

2015

Volltextzugriff (PDF)

Clinical pharmacological properties of mipomersen (Kynamro), a second generation antisense inhibitor of apolipoprotein B

British journal of clinical pharmacology, 2013-08, Vol.76 (2), p.269-276

2013

Volltextzugriff (PDF)

Antisense oligonucleotides capable of promoting specific target mRNA reduction via competing RNase H1-dependent and independent mechanisms

PloS one, 2014-10, Vol.9 (10), p.e108625-e108625

2014

Volltextzugriff (PDF)

Towards next generation antisense oligonucleotides: mesylphosphoramidate modification improves therapeutic index and duration of effect of gapmer antisense oligonucleotides

Nucleic acids research, 2021-09, Vol.49 (16), p.9026-9041

2021

Volltextzugriff (PDF)

Annexin A2 facilitates endocytic trafficking of antisense oligonucleotides

Nucleic acids research, 2016-09, Vol.44 (15), p.7314

2016

Volltextzugriff (PDF)

Antisense Oligonucleotide Inhibition of Apolipoprotein C-III Reduces Plasma Triglycerides in Rodents, Nonhuman Primates, and Humans

Circulation research, 2013-05, Vol.112 (11), p.1479-1490

2013

Volltextzugriff (PDF)

2'-Fluoro-modified phosphorothioate oligonucleotide can cause rapid degradation of P54nrb and PSF

Nucleic acids research, 2015-05, Vol.43 (9), p.4569-4578

2015

Volltextzugriff (PDF)

The rates of the major steps in the molecular mechanism of RNase H1-dependent antisense oligonucleotide induced degradation of RNA

Nucleic acids research, 2015-10, Vol.43 (18), p.8955-8963

2015

Volltextzugriff (PDF)

RNA Therapeutics in Oncology: Advances, Challenges, and Future Directions

Journal of clinical pharmacology, 2017-10, Vol.57 (S10), p.S43-S59

2017

Volltextzugriff (PDF)

Translation efficiency of mRNAs is increased by antisense oligonucleotides targeting upstream open reading frames

Nature biotechnology, 2016-08, Vol.34 (8), p.875-880

2016

Volltextzugriff (PDF)

Insights into innate immune activation via PS-ASO–protein–TLR9 interactions

Nucleic acids research, 2022-08, Vol.50 (14), p.8107-8126

2022

Volltextzugriff (PDF)

Intra-endosomal trafficking mediated by lysobisphosphatidic acid contributes to intracellular release of phosphorothioate-modified antisense oligonucleotides

Nucleic acids research, 2017-05, Vol.45 (9), p.5309-5322

2017

Volltextzugriff (PDF)

Single-Stranded siRNAs Activate RNAi in Animals

Cell, 2012-08, Vol.150 (5), p.883-894

2012

Volltextzugriff (PDF)

Origins of the Increased Affinity of Phosphorothioate-Modified Therapeutic Nucleic Acids for Proteins

Journal of the American Chemical Society, 2020-04, Vol.142 (16), p.7456-7468

2020

Volltextzugriff (PDF)

mRNA levels can be reduced by antisense oligonucleotides via no-go decay pathway

Nucleic acids research, 2019-07, Vol.47 (13), p.6900-6916

2019

Volltextzugriff (PDF)

Progress in antisense technology

Annual review of medicine, 2004-01, Vol.55 (1), p.61-95

Crooke, Stanley T

2004

Volltextzugriff (PDF)

Nucleic acid binding proteins affect the subcellular distribution of phosphorothioate antisense oligonucleotides

Nucleic acids research, 2017-10, Vol.45 (18), p.10649-10671

2017

Volltextzugriff (PDF)

Site-specific incorporation of 5'-methyl DNA enhances the therapeutic profile of gapmer ASOs

Nucleic acids research, 2021-02, Vol.49 (4), p.1828-1839

2021

Volltextzugriff (PDF)

Molecular Mechanisms of Antisense Oligonucleotides

Nucleic acid therapeutics, 2017-04, Vol.27 (2), p.70-77

Crooke, Stanley T

2017

Volltextzugriff (PDF)

1 – 25 von 471

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(352)
Mit Volltextzugriff
(294)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(471)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Science & Technology
(273)
Life Sciences & Biomedicine
(254)
Humans
(152)
Animals
(134)
Biochemistry & Molecular Biology
(132)
Biological And Medical Sciences
(79)
Pharmacology & Pharmacy
(63)
Kinetics
(46)
Male
(45)
Medical Sciences
(44)
Mice
(43)
Coping With Illness
(42)
Medicine, Research & Experimental
(39)
Pharmacology. Drug Treatments
(39)
Research & Experimental Medicine
(39)
Hela Cells
(38)
Fundamental And Applied Biological Sciences. Psychology
(36)
Oncology
(36)
Ribonuclease H - Metabolism
(32)
Base Sequence
(30)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Phosphorothioate modified oligonucleotide–protein interactions

Cellular uptake and trafficking of antisense oligonucleotides

Development of a Quantitative BRET Affinity Assay for Nucleic Acid-Protein Interactions

Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials

Single-Stranded RNAs Use RNAi to Potently and Allele-Selectively Inhibit Mutant Huntingtin Expression

Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index

Clinical and Preclinical Pharmacokinetics and Pharmacodynamics of Mipomersen (Kynamro®): A Second-Generation Antisense Oligonucleotide Inhibitor of Apolipoprotein B

Clinical pharmacological properties of mipomersen (Kynamro), a second generation antisense inhibitor of apolipoprotein B

Antisense oligonucleotides capable of promoting specific target mRNA reduction via competing RNase H1-dependent and independent mechanisms

Towards next generation antisense oligonucleotides: mesylphosphoramidate modification improves therapeutic index and duration of effect of gapmer antisense oligonucleotides

Annexin A2 facilitates endocytic trafficking of antisense oligonucleotides

Antisense Oligonucleotide Inhibition of Apolipoprotein C-III Reduces Plasma Triglycerides in Rodents, Nonhuman Primates, and Humans

2'-Fluoro-modified phosphorothioate oligonucleotide can cause rapid degradation of P54nrb and PSF

The rates of the major steps in the molecular mechanism of RNase H1-dependent antisense oligonucleotide induced degradation of RNA

RNA Therapeutics in Oncology: Advances, Challenges, and Future Directions

Translation efficiency of mRNAs is increased by antisense oligonucleotides targeting upstream open reading frames

Insights into innate immune activation via PS-ASO–protein–TLR9 interactions

Intra-endosomal trafficking mediated by lysobisphosphatidic acid contributes to intracellular release of phosphorothioate-modified antisense oligonucleotides

Single-Stranded siRNAs Activate RNAi in Animals

Origins of the Increased Affinity of Phosphorothioate-Modified Therapeutic Nucleic Acids for Proteins

mRNA levels can be reduced by antisense oligonucleotides via no-go decay pathway

Progress in antisense technology

Nucleic acid binding proteins affect the subcellular distribution of phosphorothioate antisense oligonucleotides

Site-specific incorporation of 5'-methyl DNA enhances the therapeutic profile of gapmer ASOs

Molecular Mechanisms of Antisense Oligonucleotides

Suchergebnisse filtern